So let me see if this poor marsupial brain has got this right.
We've had two significant trial readouts this week and both missed their primary end points.
So either the products aren't up to scratch or the end points weren't appropriate.
As there is significant evidence that the products are good
Then we can conclude that the primary end points were inappropriate.
If so, what is the cause of this massive design failure?
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-535
-
- There are more pages in this discussion • 541 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 274918 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 974 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |